Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Events

10 May 2016 - 16 May 2016
11 May 2016 - 13 May 2016

Antisynuclein Monoclonal Antibody Reverses Parkinson's Disease Symptoms in Culture and Mouse Models

By BiotechDaily International staff writers
Posted on 23 Jun 2014
Print article
Image: Lewy body (brown) from the brain of a Parkinson\'s disease patient (Photo courtesy of the University of Pennsylvania).
Image: Lewy body (brown) from the brain of a Parkinson\'s disease patient (Photo courtesy of the University of Pennsylvania).
The development of Parkinson's disease in a mouse model was blocked by treatment with monoclonal antibodies directed at alpha-synuclein (alpha-syn), the main protein component of the Lewy bodies and Lewy neurites that characterize the disease.

A Lewy body is composed of the protein alpha-synuclein associated with other proteins, such as ubiquitin, neurofilament protein, and alpha B crystalline. Similar to Lewy bodies, Lewy neurites are proteinaceous formations found in neurons of the diseased brain, comprising abnormal alpha-syn filaments and granular material. Like Lewy bodies, Lewy neurites are a feature of alpha-synucleinopathies such as dementia with Lewy bodies, Parkinson's disease, and multiple system atrophy. They are also found in the CA2-3 region of the hippocampus in Alzheimer's disease.

Investigators at the University of Pennsylvania (Philadelphia, USA) worked with culture and mouse models of Parkinson's disease that they had established during prior studies. Using these model systems they had found that synthetic preformed alpha-syn fibrils recruited endogenous alpha-syn and induced Lewy body/Lewy neurite pathology in neuron cultures and test animals, thereby implicating propagation and cell-to-cell transmission of pathological alpha-syn as mechanisms for the progressive spread of Lewy bodies and Lewy neurites.

In the current study they introduced the anti-alpha-syn monoclonal antibody Syn303 into the model systems. They reported in the June 12, 2014, online edition of the journal Cell Reports that alpha-syn monoclonal antibodies reduced alpha-syn preformed fibrils-induced Lewy body/Lewy neurite formation and rescued synapse and neuron loss in primary neuronal cultures by preventing both uptake of the preformed fibrils and subsequent cell-to-cell transmission of the disease pathology. Moreover, intraperitoneal (i.p.) administration of the Syn303 antibody into mice injected with alpha-syn preformed fibrils reduced Lewy body/Lewy neurite pathology, ameliorated neuron loss, and improved motor impairments.

"Once we created these models, the first thing that came to mind is immunotherapy," said senior author Dr. Virginia M.Y Lee, professor of pathology and laboratory medicine at the University of Pennsylvania. "If you can develop antibodies that would stop the spreading, you may have a way to at least retard the progression of Parkinson's disease. In animal models the question we want to ask is, can we reduce the pathology and also rescue cell loss to improve the behavioral deficits? But there are some limitations to experiments in live mice since it is difficult to directly study the mechanism of how it works. To do that, we went back to the cell culture model to ask whether or not the antibody basically prevents the uptake of misfolded alpha-syn. The cell culture experiments showed that MAbs prevented the uptake of misfolded alpha-syn fibrils by neurons and sharply reduced the recruitment of natural alpha-syn into new Lewy body aggregates."

Related Links:

University of Pennsylvania



Print article

Channels

Drug Discovery

view channel

Experimental Small-Molecule Anticancer Drug Blocks RAS-binding Domains

The experimental small-molecule anticancer drug rigosertib was shown to block tumor growth by acting as an RAS-mimetic and interacting with the RAS binding domains of RAF kinases, resulting in their inability to bind to RAS, which inhibited the RAS-RAF-MEK pathway. Oncogenic activation of RAS genes due to point mutations... Read more

Biochemistry

view channel
Image: A space-filling model of the anticonvulsant drug carbamazepine (Photo courtesy of Wikimedia Commons).

Wastewater May Contaminate Crops with Potentially Dangerous Pharmaceuticals

Reclaimed wastewater used to irrigate crops is contaminated with pharmaceutical residues that can be detected in the urine of those who consumed such produce. Investigators at the Hebrew University... Read more

Lab Technologies

view channel

Huge Modifiable Biomedical Database to Be Available on the Wikidata Site

Genome researchers are exploiting the power of the open Internet community Wikipedia database to create a comprehensive resource for geneticists, molecular biologists, and other interested life scientists. While efficiency in generating scientific data improves almost daily, applying meaningful relationships between... Read more

Business

view channel

European Biotech Agreement to Promote Antigen-Drug Conjugation Technology

Two European biotech companies have joined forces to exploit and commercialize an innovative, site-specific ADC (antigen-drug conjugate) conjugation technology. ProBioGen (Berlin, Germany), a company specializing in the development and manufacture of complex glycoproteins and Eucodis Bioscience (Vienna, Austria), a... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.